Since sclerostin, an inhibitor of the Wnt/β-catenin pathway that impairs bone formation, has become an attractive therapeutic target for treating osteoporosis, we wondered if this molecule could also be produced by muscle cells. This evidence concerns the gene SOST and osteoporosis.